INFORMACION PARA IMPUGNAR "ECLOTINIB"

chusky

Nuevo Miembro
2 Feb 2009
1
0
1
#1
HARRISON 17º ED.

Part 6. Oncology and Hematology.

85. Neoplasms of the lung

EGFR Targeted Therapy:
Erlotinib is an oral inhibitor of the EGFR kinase that is used in second- and third-line therapy of NSCLC. Clinical responses have been seen in a large fraction of the small subset of patients with tumors bearing mutations in the EGFR. Prolonged survival with EGFR TKI treatment has also been observed in some patients whose tumors have amplification of the EGFR gene or overexpression of the receptor. Side effects of erlotinib differ from chemotherapy side effects of hair loss, nausea, and neutropenia, but they include acneiform skin rash and diarrhea. For patients whose tumors respond to EGFR TKI therapy, substantial clinical benefit is seen.